/EIN News/ — Thousand Oaks, CA, Dec. 07, 2020 (GLOBE NEWSWIRE) — CBDual Biotechnology Corp., a subsidiary of THC Farmaceuticals, Inc (OTC PINK: CBDG) developer of a unique line of premium CBD based oral health products, today announced that it had completed the research and development of a groundbreaking new CBD based dental anxiety formulation that will be available next week for purchase on CBDUAL’S website and participating dental offices.
Research shows that cannabidiol (CBD) can help ameliorate severe medical symptoms from multiple sclerosis, cancer, Parkinson’s, Alzheimer’s, anxiety, and depression.
CBD products have been of interest in treating both socially and physically-based anxiety disorders. The FDA approved the use of cannabidiol in treating epilepsy. A recent clinical trial has shown that CBD can effectively reduce anxiety.
The Permanente Journal published a study reporting that 79% of participants experienced a reduction in anxiety after ingesting cannabinoids. Hence, these preliminary results on CBD’s positive effects have caused mental health advocates to consider CBDs for their anti-anxiety properties.
Even though the way CBD works to treat anxiety isn’t fully understood, it hasn’t stopped millions of people in need of symptom relief from using CBDs. It is reported in a 2019 Gallup Poll that 14% of…
